About ImmunityBio, Inc.
NK & T Cell
ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine platform.
The research and development of cell therapy product candidates require an exceptional team of people with scientific and clinical expertise across a range of disciplines. We seek to forge collaborations with leading strategic partners, key researchers, and top medical centers to accelerate the development of our first-in-class product candidates and modalities.
Please email firstname.lastname@example.org to reach out to our partnering team for further discussion.